Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript

Vivek Jayaraman: Sure, yes, happy to address that. One of the key milestones was getting under contract with large blood centers here in the US. We’re currently under contract for IFC with blood centers that represent roughly 60% of the cryoprecipitate market in the US. The key thing now is just continuing to translate clinician level demand into committed hospital interest and having the ability for those hospitals to receive product from their blood supply the current good supplier is a huge enabler in that regard. So we feel pretty enthusiastic about that business, given the combination of these key contracts that have not been executed a fully staffed and trained hospital sales force that’s getting in and having a number of meetings with clinicians and directly with hospitals.

And then the continued sort of clinical uptake and peer-to-peer marketing opportunities we see as we bring more hospitals on board in terms of IFC users. So on balance, the combination of all those factors leads us to be very optimistic about this business heading into the next calendar year.

Unidentified Analyst: Thanks for taking my questions.

Operator: Thank you. [Operator Instructions] I don’t see any further questions in queue. I would like to turn the call over to Obi Greenman for closing comments.

Obi Greenman: Well, thank you again for joining us today and for your interest in Cerus. We look forward to updating you on our continued progress this year and next. Thanks very much.

Operator: And with that, we thank you for participating in today’s conference. You may now disconnect.